TCRR — TCR2 Therapeutics Share Price
0.000.00%
Last trade - 00:00- $58.11m
- -$52.20m
- 35
- 47
- 64
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.57 | ||
| Price to Tang. Book | 0.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -159.36% | ||
| Return on Equity | -91.46% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The Company completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Directors
- Ansbert Gadicke NEC (63)
- Garry Menzel PRE (57)
- Angela Justice CHO (49)
- Robert Hofmeister CSO (53)
- Alfonso Cardama OTH (50)
- Andrew Allen IND (55)
- Neil Gibson IND (65)
- Priti Hegde IND (49)
- Axel Hoos IND (51)
- Shawn Tomasello IND (62)
- Stephen Webster IND (60)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- May 29th, 2015
- Public Since
- February 14th, 2019
- No. of Shareholders
- 14
- No. of Employees
- 58
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 39,261,745
- Address
- 100 Binney St, CAMBRIDGE, 02142-1096
- Web
- https://www.tcr2.com/
- Phone
- +1 6179495200
- Auditors
- KPMG LLP
Upcoming Events for TCRR
TCR2 Therapeutics Inc Annual Shareholders Meeting
Q3 2023 TCR2 Therapeutics Inc Earnings Release
Similar to TCRR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the TCR2 Therapeutics share price?
As of Today at 19:22 UTC, shares in TCR2 Therapeutics are trading at $1.48. This share price information is delayed by 15 minutes.
How has the TCR2 Therapeutics share price performed this year?
Shares in TCR2 Therapeutics last closed at $1.48 and the price had moved by -36.21% over the past 365 days. In terms of relative price strength the TCR2 Therapeutics share price has underperformed the S&P500 Index by -38.8% over the past year.
What are the analyst and broker recommendations for TCR2 Therapeutics?
The overall consensus recommendation for TCR2 Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the TCR2 Therapeutics dividend yield?
TCR2 Therapeutics does not currently pay a dividend.
Does TCR2 Therapeutics pay a dividend?
TCR2 Therapeutics does not currently pay a dividend.
When does TCR2 Therapeutics next pay dividends?
TCR2 Therapeutics does not currently pay a dividend.
How do I buy TCR2 Therapeutics shares?
To buy shares in TCR2 Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TCR2 Therapeutics?
As of the previous close price of $1.48, shares in TCR2 Therapeutics had a market capitalisation of $58.11m.
Where are TCR2 Therapeutics shares listed?
Here are the trading details for TCR2 Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TCRR
What kind of share is TCR2 Therapeutics?
Based on an overall assessment of its quality, value and momentum TCR2 Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TCR2 Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in TCR2 Therapeutics is $6.43. That is 334.46% above the last closing price of $1.48.
Analysts covering TCR2 Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.41 for the next financial year.
What is the trend in the TCR2 Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TCR2 Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -1.99%.
As of the last closing price of $1.48, shares in TCR2 Therapeutics were trading -9.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TCR2 Therapeutics PE Ratio?
The TCR2 Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TCR2 Therapeutics?
TCR2 Therapeutics' management team is headed by:
- Ansbert Gadicke - NEC
- Garry Menzel - PRE
- Angela Justice - CHO
- Robert Hofmeister - CSO
- Alfonso Cardama - OTH
- Andrew Allen - IND
- Neil Gibson - IND
- Priti Hegde - IND
- Axel Hoos - IND
- Shawn Tomasello - IND
- Stephen Webster - IND